Publications by the researcher in collaboration with Araceli Alonso Cánovas (44)

2024

  1. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice

    Neurologia, Vol. 39, Núm. 4, pp. 340-344

2023

  1. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  2. Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study

    Parkinsonism and Related Disorders

  3. Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: A national multicentre observational study

    Journal of Neurology, Neurosurgery and Psychiatry

  4. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review

    Brain Sciences, Vol. 13, Núm. 2

  5. ¿Qué piensan los estudiantes de Medicina sobre los trastornos neurológicos funcionales?

    Revista de neurologia, Vol. 76, Núm. 8, pp. 265-271

2022

  1. Efficacy and safety of high doses of safinamide in advanced Parkinson disease

    Parkinsonism and Related Disorders

  2. Eye-of-the-Tiger Sign with an Unexpected Pathological Diagnosis

    Movement Disorders Clinical Practice, Vol. 9, Núm. 1, pp. 98-103

2021

  1. Apomorphine: A powerful ally in parkinson's disease

    Revista de Neurologia, Vol. 72, Núm. 9, pp. 323-332

  2. COVID-19 in Parkinson’s disease: what holds the key?

    Journal of Neurology, Vol. 268, Núm. 8, pp. 2666-2670

  3. Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review

    Movement Disorders Clinical Practice, Vol. 8, Núm. 1, pp. 25-32

  4. Impact of SAfinamide on depressive symptoms in parkinson’s disease patients (SADness-PD Study): A multicenter retrospective study

    Brain Sciences, Vol. 11, Núm. 2, pp. 1-11

  5. Impulse Control Disorders in Parkinson's Disease: Has COVID-19 Related Lockdown Been a Trigger?

    Movement Disorders Clinical Practice, Vol. 8, Núm. 6, pp. 940-943

  6. Management of Parkinson's disease and other movement disorders in woman of childbearing age: Part 1

    Neurologia, Vol. 36, Núm. 2, pp. 149-158

  7. Management of Parkinson's disease and other movement disorders in women of childbearing age: Part 2

    Neurologia, Vol. 36, Núm. 2, pp. 159-168

  8. Mutational spectrum of GNAL, THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review

    European Journal of Neurology, Vol. 28, Núm. 4, pp. 1188-1197

  9. Predictors of clinically significant quality of life impairment in Parkinson’s disease

    npj Parkinson's Disease, Vol. 7, Núm. 1

2020

  1. Clinical experience in the treatment of motor fluctuations in Parkinson's disease. Delphi consensus of a group of experts in movement disorders

    Revista de Neurologia, Vol. 71, Núm. 11, pp. 407-420

  2. Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease

    Journal of Parkinson's Disease, Vol. 10, Núm. 4, pp. 1611-1620

  3. Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

    Scientific Reports, Vol. 10, Núm. 1